Advisors – BioXcel Therapeutics Inc

Advisors

Artificial Intelligence (AI)

Vít Novacek is Associate Professor at Faculty of Informatics, Masaryk University, Czech Republic. He is also affiliated with the Data Science Institute at National University…

Corporate/Clinical

Dr. Gujrathi is the Co-Founder and Chief Executive Officer of Gossamer Bio. She most recently served as Chief Medical Officer of Receptos, an immunology-focused biotechnology…

Dr. Rajiv Patni was Chief Research and Development Officer at Reata Pharmaceuticals a commercial-stage company recently acquired by Biogen. Previously, he was a successful…

Immuno-oncology

Dr. Rahul Aggarwal is a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco (UCSF). His clinical practice focuses…

Daniel D. Von Hoff, M.D., F.A.C.P. is currently Executive Vice President and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona…

Dr. Louis Weiner is Director of Georgetown Lombardi Comprehensive Cancer Center, one of 49 National Cancer Institute (NCI)-designated comprehensive cancer…

Daniel D. Von Hoff, M.D., F.A.C.P. is currently Executive Vice President and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for HonorHealth Clinical Research Institute and Chair of the Early Drug Development Committee at McKesson Specialty Health, U.S. Oncology Research. He is also Professor of Medicine, Mayo Clinic Scottsdale, Arizona. Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA-approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, isomeric, nab-paclitaxel, nal-IRI, and others. His clinical trial work has led to the approval of three of the four drugs approved by the FDA for treatment of patients with advanced pancreatic cancer.

At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 767 papers, 140 book chapters, and over 1190 abstracts. He received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. He is past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after ILEX had two agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and Editor Emeritus of Investigational New Drugs –The Journal of New Anticancer Agents – and past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2000 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Dr. Louis Weiner is Director of Georgetown Lombardi Comprehensive Cancer Center, one of 49 National Cancer Institute (NCI)-designated comprehensive cancer centers in the United States. He holds the Francis L. and Charlotte G. Gragnani Chair and is Professor of Oncology and Chair of the Department of Oncology at Georgetown University Medical Center. He also serves as Director of the MedStar Georgetown Cancer Institute, a cancer service line serving patients in the Washington DC and Baltimore metropolitan areas. He is responsible for the operation and development of the cancer center, including its research, clinical, and educational missions. The clinical mission includes leading the MedStar-Georgetown Cancer Network in the metropolitan Washington area. Dr. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and related modalities of therapy. His current research focuses on identifying and therapeutically exploiting mechanisms employed by malignant cells to combat immune destruction, with a focus on pancreatic cancer.

Prior to joining Georgetown Lombardi as director in 2008, Dr. Weiner served as Chairman of the medical oncology department and Vice President for Translational Research at Fox Chase Cancer Center in Philadelphia and served as professor in the department of medicine at Temple University School of Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research (AACR) and founded the AACR Cancer Immunology Working Group. He has served as chair of the NCI Board of Scientific Counselors for Clinical Sciences and Epidemiology and as a member of the NCI Clinical Trials Advisory Committee (CTAC). He also served on the NCI’s blue ribbon panel working group on immunotherapy for the National Cancer Moonshot Initiative and Advisory Panel of the National Institutes of Health (NIH) Center for Scientific Research (CSR), which administers NIH research grants. He is recipient of the 2019 AACR Distinguished Public Service Award.

Dr. Weiner earned his bachelor’s degree in biology with honors from the University of Pennsylvania and his M.D. from Mount Sinai School of Medicine. After completing his internship, residency, and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston.